Aeglea Biotherapeutics

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company designing and developing human enzyme therapies for the treatment of patients with rare genetic diseases and cancer. The company’s lead product candidate is pegzilarginase, a recombinant human arginase 1 enzyme in early clinical development for the treatment of autosomal recessive metabolic disorders caused by significantly reduced natural arginase 1 enzyme activity and arginine-dependent cancers.